In the study of Movahedi et al., an excess of unlabeled, bivalent anti-MMR sdAbs were co-injected with monovalent anti-MMR sdAbs to reduce sdAb accumulation in extra-tumoral organs to background levels, without compromising tumor uptake 29. Here, MRC1 is linked to neoplasm.